Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9263281 | 0.88 | FKBP1A (0.48) | FKBP1AHTR2CSMN1; SMN2 | |
| SCHEMBL7300300 | 0.88 | FKBP1A (0.48) | FKBP1AHTR2CSMN1; SMN2 | |
| SCHEMBL4674934 | 0.86 | HTR2C (0.52) | FKBP1AHTR2CCYP2C19SMN1; SMN2 | |
| SCHEMBL7264269 | 0.81 | FKBP1A (0.62) | FKBP1A | |
| Hydrochloric Acid SCHEMBL7265458 | 0.81 | FKBP1A (0.61) | FKBP1A | |
| SCHEMBL9259424 | 0.81 | KLK7 (0.48) | FKBP1AHTR2C | |
| SCHEMBL29072821 | 0.80 | HTR2C (0.50) | FKBP1AHTR2CSMN1; SMN2 | |
| SCHEMBL27736628 | 0.80 | HTR2C (0.51) | FKBP1AHTR2C | |
| SCHEMBL27757498 | 0.80 | HTR2C (0.51) | FKBP1AHTR2C | |
| SCHEMBL8948803 | 0.79 | CYP2C19 (0.48) | FKBP1AHTR2CCYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132295-B2 | Isotopically coded affinity markers 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2006-11-07 | — | — | US | disclosed |
| US-20050049406-A1 | Isotopically coded affinity markers 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-03 | — | — | US | disclosed |
| EP-1446665-A2 | ISOTOPICALLY CODED AFFINITY MARKERS 3 | Bayer HealthCare AG (DE) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003040288-A2 | ISOTOPICALLY CODED AFFINITY MARKERS 3 | BAYER HEALTHCARE AG (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049406-A1 | Isotopically coded affinity markers 3 | IGFBP3, FABP3, LGALS3BP | FKBP1A 331/4885HTR2C 4458/4885CA1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.